Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity.

The best characterized pathways are the orexigenic neuropeptide Y/Agouti-related protein and the anorexigenic pro-opiomelanocortin/cocaine- and amphetamine-related transcript neurons in the ...

Using a variety of approaches, the authors show that this switch is mediated by the neuropeptide, sulfakinin, acting peripherally through the sulfakinin receptor 1 to regulate the expression of ...

Boehringer Ingelheim has halted development of an obesity drug from Gubra that it originally pledged to advance back in 2017, ...

Researchers uncover a link between impaired glutathione–ascorbate metabolism and early dopamine increases in Huntington's ...

The hypothalamus integrates neurohormonal signaling from gut and adipose tissue. Specific hypothalamic nuclei, including the dorsomedial nucleus (DMN), paraventricular nucleus (PVN) and ...

重点推荐扫码下载《动物模型构建与行为评估》pdf《动物模型构建与行为评估》pdf电子版 ...

Researchers at Brown University have found how a neuropeptide hormone produced in the gut of flies can control their lifespan ... These gut hormones include pancreatic polypeptide Y (PPY) and glucagon ...

This important study reports that the neurohormone, bursicon, and its receptor, play a role in the seasonal polyphenism of the bug Cacopsylla chinensis. Low temperature activates the bursicon ...

Palatin Technologies, Inc. , a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the ...